LINC00205 and neoplasm: A study showed that, as a competing endogenous RNA with lower expression levels in tumor tissues, LINC00205 may negatively regulate HCC progression via the miR-184/EPHX1 axis (Long et al., 2019), While another study indicated that LINC00205, can serve as an oncogene, and can promote the proliferation, migration and invasion of HCC cells by targeting miR-122-5p (Zhang et al., 2019a).